Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Expands Heparin Sodium Injection Portfolio To Seven Products
Details : Heparin sodium is an anticoagulant, or "blood thinner," used to prevent and treat blood clots by inhibiting thrombin and other clotting factors via the antithrombin III complex.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2025
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Gains FDA Approval for DUPLEX Delivery of Piperacillin Combo
Details : Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.
Product Name : Piperacillin and Tazobactam for Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin Sodium,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Ready-to-Activate Cefazolin 3 Gram Pre-Mix in DUPLEX® Containers
Details : Cefazolin sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It is indicated for several infections, like respiratory, urinary infections in adult and pediatric.
Product Name : Cefazolin Sodium Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 24, 2025
Lead Product(s) : Cefazolin Sodium,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Levetiracetam in Sodium Chloride Injection Portfolio
Details : Levetiracetam is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.
Product Name : Levetiracetam-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva® Acquires Critical Cell Therapy Manufacturing Assets From B. Braun
Details : The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells.
Product Name : Epidex
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
November 21, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Details : Cefazolin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 25, 2022
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable